<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01543672</url>
  </required_header>
  <id_info>
    <org_study_id>M11VOL</org_study_id>
    <nct_id>NCT01543672</nct_id>
  </id_info>
  <brief_title>Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously</brief_title>
  <acronym>VOLUMES</acronym>
  <official_title>VOLUMES Treatment of Larger Tumor Volumes or ≥ 2 Lung Tumors Simultaneously in Lung Cancer Patients Using SBRT in a Mean-lung Dose Escalation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of larger tumor volumes or ≥ 2 lung metastases simultaneously in lung cancer
      patient using Stereotactic Body Radiation Therapy (SBRT) in a mean-lung dose escalation
      study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase I/II multicenter trial will be conducted in patients with medically inoperable with
      peripheral non small cell lung cancer (NSCLC) &gt; 5 cm without lymph node involvement (group
      A) or medically with ≥ 2 or more lung metastases (group B). Radiation pneumonitis is
      expected to be dose-limiting in these patients and there is evidence that the incidence is
      predicted by the mean lung dose (MLD). The MLD escalation will be performed separately in
      both patient groups, using a time-to-event continual reassessment method (TITE-CRM). All
      patients will receive 3-5 fractions SBRT to the lung tumor(s), with a minimum mean PTV dose
      ≥ 42 Gy. Fraction size may be downscaled based on the MLD constraint.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>MLD</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The assessment of the maximum mean lung dose that can be safely treated with SBRT and that is associated with a 20% probability of the DLT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>loco-regional control</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine the local control and regional control as a function of the mean lung dose, the largest toxicity effects as a function of the MLD and the overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determine the local control and regional control as a function of the mean lung dose, the largest toxicity effects as a function of the MLD and the overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>valuate the increase or decrease of physical discomfort.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Metastatic Lung Cancer</condition>
  <arm_group>
    <arm_group_label>SBRT group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>escalate MLD in medically inoperable patients with tumors larger than 5 cm in diameter (primary or solitary metastases)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SBRT group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalate the MLD in patients with ≥ 2 lung metastases</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiotherapy (SBRT)</intervention_name>
    <description>3-5 fractions within 10-14 days</description>
    <arm_group_label>SBRT group A</arm_group_label>
    <other_name>Stereotactic Body Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiotherapy (SBRT)</intervention_name>
    <description>3-5 fractions per tumor within one treatment session or sequential within one month</description>
    <arm_group_label>SBRT group B</arm_group_label>
    <other_name>Stereotactic Body Radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for group A and B:

          -  Weight loss &lt; 10% in the last three months.

          -  WHO-performance status ≤ 2

          -  Medical inoperable patients or patients refusing surgery.

          -  Chemotherapy is allowed in neoadjuvant and adjuvant setting, with exclusion of the
             period 4 weeks pre-SBRT and 6 weeks post-SBRT.

          -  Before patient registration, written informed consent must be given according to
             ICH/GCP, national and local regulations.

        Risk group A specification:

          -  NSCLC (Cytological or histological proven) patients with peripheral tumors &gt;5 cm with
             tumor staging cT2bN0M0 or cT3N0M0 (chest wall infiltration is no exclusion criteria,
             as long as the tumor diameter is &gt; 5 cm).

          -  Single peripheral lung metastasis in inoperable patients with a diameter of &gt; 5 cm.
             In case of first presentation of metastatic disease, cytological or histological
             proof is obligated.

          -  In patients without cytological or histological confirmation of NSCLC, a growing
             FDG-PET positive lesion (SUV &gt;5) is accepted if a contra-indication for invasive
             diagnostic examination (or refusal) is present.

        Risk group B specification:

          -  Patients with ≥ 2 simultaneous peripheral lung metastases ≤ 5 cm of any origin at any
             location in the lung.

          -  In case of first presentation of metastatic disease, cytological or histological
             proof is obligated. This is not necessary in case of a history of an already proven
             disseminated disease.

          -  Patients having ≥ 2 peripheral lung metastases without unacceptable dose overlap.

        Exclusion Criteria:

          -  Patients with central tumors

          -  Pancoast tumors

          -  Prior radiotherapy treatment to the thorax

          -  Patients receiving any systemic treatment during SBRT

          -  Pregnant patients

          -  Patients previously treated with adriamycin agents in case of heart involvement
             within the treatment field.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heike Peulen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heike Peulen, MD</last_name>
    <phone>+31 20 512 2135</phone>
    <email>h.peulen@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jose Belderbos, MD, PhD</last_name>
    <phone>+31 20 512 2135</phone>
    <email>j.belderbos@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beaumont Hospital, Royal Oak</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inga Grills, MD</last_name>
      <phone>248-551-7090</phone>
      <email>IGrills@beaumont.edu</email>
    </contact>
    <investigator>
      <last_name>Inga Grills, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University/ Kimmel Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>PA 19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Werner-Wasik, M.D., PhD</last_name>
      <phone>215-955-6000</phone>
      <email>Maria.Werner-Wasik@jeffersonhospital.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prinses Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Hope, M.D., PhD</last_name>
      <email>Andrew.Hope@rmp.uhn.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Meredith Giuliani, M.D., PhD</last_name>
      <email>Meredith.Giuliani@rmp.uhn.on.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>DE-97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Metz, MD, PhD</last_name>
      <phone>+49 931-201-28984</phone>
    </contact>
    <contact_backup>
      <last_name>M Metz, MD, PhD</last_name>
      <phone>+49 931-201-28984</phone>
      <email>Metz_M2@ukw.de</email>
    </contact_backup>
    <investigator>
      <last_name>M Metz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NKI-AVL</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heike Peulen, MD</last_name>
      <phone>+31 20 5122135</phone>
      <email>h.peulen@nki.nl</email>
    </contact>
    <contact_backup>
      <last_name>Jose Belderbos, MD, PhD</last_name>
      <phone>+3 20 5122135</phone>
      <email>j.belderbos@nki.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Heike Peulen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 3, 2016</lastchanged_date>
  <firstreceived_date>February 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung</keyword>
  <keyword>SBRT</keyword>
  <keyword>MLD</keyword>
  <keyword>toxicity</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
